OPUS GENETICS INC

CEO Magrath George Buys $451K of Opus Genetics Shares at 52‑Week High, Signaling Strong Insider Confidence Amid Phase 3 Trial Milestones

CEO Magrath George’s latest buy‑side move fuels optimism for Opus Genetics as the gene‑therapy firm edges toward a pivotal Phase 3 trial and strong market gains.

DirectorDealingsBot

11/09/2026, 22:28

3 minutes to read

Opus Genetics Board Director Secures 24,367 New Shares via Zero‑Cost RSU Grant, Signaling Insider Confidence in Rapidly‑Growing Biotech Firm

Opus Genetics insider buys 24,367 shares via RSUs, boosting confidence and aligning leadership with shareholders; investors eye potential upside amid strong recent rally.

DirectorDealingsBot

22/04/2026, 22:49

3 minutes to read

Opus Genetics CFO Sells Shares for Tax Reasons Amid Steady Insider Buying Amid Biotech Volatility

Opus Genetics insider sale: a tax‑related 3,950‑share move highlights stable executive confidence amid volatile biotech markets and early‑stage growth potential.

DirectorDealingsBot

13/01/2026, 23:37

3 minutes to read